CN115697417A - Nectin-4特异性的双环肽配体及其用途 - Google Patents
Nectin-4特异性的双环肽配体及其用途 Download PDFInfo
- Publication number
- CN115697417A CN115697417A CN202180043142.4A CN202180043142A CN115697417A CN 115697417 A CN115697417 A CN 115697417A CN 202180043142 A CN202180043142 A CN 202180043142A CN 115697417 A CN115697417 A CN 115697417A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- patient
- acceptable salt
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063027536P | 2020-05-20 | 2020-05-20 | |
| US63/027,536 | 2020-05-20 | ||
| PCT/GB2021/051220 WO2021234391A1 (en) | 2020-05-20 | 2021-05-20 | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115697417A true CN115697417A (zh) | 2023-02-03 |
Family
ID=76532225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180043142.4A Pending CN115697417A (zh) | 2020-05-20 | 2021-05-20 | Nectin-4特异性的双环肽配体及其用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181749A1 (https=) |
| EP (1) | EP4153240A1 (https=) |
| JP (1) | JP2023526451A (https=) |
| KR (1) | KR20230037502A (https=) |
| CN (1) | CN115697417A (https=) |
| AU (1) | AU2021276616A1 (https=) |
| CA (1) | CA3179152A1 (https=) |
| IL (1) | IL298382A (https=) |
| MX (1) | MX2022014550A (https=) |
| WO (1) | WO2021234391A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117003830A (zh) * | 2023-08-04 | 2023-11-07 | 湖南中晟全肽生化有限公司 | 靶向Nectin-4的多肽及其用途 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| EP3645549A1 (en) | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| CN111902429A (zh) | 2018-02-23 | 2020-11-06 | 拜斯科技术开发有限公司 | 多聚体双环肽配体 |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| US12492224B2 (en) | 2018-12-21 | 2025-12-09 | Bicycletx Limited | Bicyclic peptide ligands specific for PD-L1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| AU2021322934A1 (en) | 2020-08-03 | 2023-03-30 | Bicycletx Limited | Peptide-based linkers |
| CN121511098A (zh) * | 2023-06-01 | 2026-02-10 | 拜斯科技术开发有限公司 | 对nectin-4具有特异性的双环肽配体及其用途 |
| WO2024248859A1 (en) * | 2023-06-01 | 2024-12-05 | Bicycletx Limited | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
| AU2024342769A1 (en) * | 2023-09-13 | 2026-04-23 | Bicycletx Limited | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190184025A1 (en) * | 2017-12-19 | 2019-06-20 | Bicycletx Limited | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 |
| US20190389906A1 (en) * | 2018-06-22 | 2019-12-26 | Bicycletx Limited | Bicyclic peptide ligands specific for nectin-4 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ283516B6 (cs) * | 1996-09-12 | 1998-04-15 | Galena A.S. | Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů |
| WO2010056796A1 (en) * | 2008-11-12 | 2010-05-20 | Theraclone Sciences, Inc. | Human m2e peptide immunogens |
| JP6595458B2 (ja) * | 2013-09-20 | 2019-10-23 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ |
| AU2015320545C1 (en) * | 2014-09-24 | 2020-05-14 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| IL324591A (en) * | 2017-08-31 | 2026-01-01 | Daiichi Sankyo Co Ltd | Improved antibody-drug conjugate production methods |
| WO2020178574A1 (en) * | 2019-03-04 | 2020-09-10 | Bicyclerd Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
| JOP20210284A1 (ar) * | 2019-04-24 | 2023-01-30 | Janssen Pharmaceuticals Inc | الإعطاء غير المتجانس للقاحات تاو |
| CN113527486B (zh) * | 2020-04-21 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 一种抗Nectin-4的抗体及其应用 |
| EP4208259A2 (en) * | 2020-09-04 | 2023-07-12 | NovaRock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
-
2021
- 2021-05-20 US US17/926,454 patent/US20230181749A1/en active Pending
- 2021-05-20 IL IL298382A patent/IL298382A/en unknown
- 2021-05-20 WO PCT/GB2021/051220 patent/WO2021234391A1/en not_active Ceased
- 2021-05-20 CN CN202180043142.4A patent/CN115697417A/zh active Pending
- 2021-05-20 JP JP2022570573A patent/JP2023526451A/ja active Pending
- 2021-05-20 MX MX2022014550A patent/MX2022014550A/es unknown
- 2021-05-20 AU AU2021276616A patent/AU2021276616A1/en active Pending
- 2021-05-20 EP EP21733852.4A patent/EP4153240A1/en active Pending
- 2021-05-20 KR KR1020227044522A patent/KR20230037502A/ko active Pending
- 2021-05-20 CA CA3179152A patent/CA3179152A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190184025A1 (en) * | 2017-12-19 | 2019-06-20 | Bicycletx Limited | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 |
| US20190389906A1 (en) * | 2018-06-22 | 2019-12-26 | Bicycletx Limited | Bicyclic peptide ligands specific for nectin-4 |
Non-Patent Citations (3)
| Title |
|---|
| BERLIN, DE: ""Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153", 《CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG》, vol. 81, no. 4, 13 February 2018 (2018-02-13), pages 679 - 686, XP036458073, DOI: 10.1007/s00280-018-3527-6 * |
| 姚静: "《药用辅料应用指南》", 31 August 2011, 中国医药科技出版社, pages: 221 - 222 * |
| 陈永法: "《药品注册法律法规》", 30 September 2011, 中国医药科技出版社, pages: 160 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117003830A (zh) * | 2023-08-04 | 2023-11-07 | 湖南中晟全肽生化有限公司 | 靶向Nectin-4的多肽及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021276616A1 (en) | 2023-01-05 |
| IL298382A (en) | 2023-01-01 |
| EP4153240A1 (en) | 2023-03-29 |
| US20230181749A1 (en) | 2023-06-15 |
| KR20230037502A (ko) | 2023-03-16 |
| JP2023526451A (ja) | 2023-06-21 |
| MX2022014550A (es) | 2023-03-02 |
| WO2021234391A1 (en) | 2021-11-25 |
| CA3179152A1 (en) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115697417A (zh) | Nectin-4特异性的双环肽配体及其用途 | |
| EP4065085A1 (en) | Bicyclic peptide ligands specific for epha2 and uses thereof | |
| WO2023089308A1 (en) | Methods for treating cancer | |
| US20250282858A1 (en) | Anti-gdf15 antibody and a dosage regimen for the treatment of cancer | |
| EP4719480A1 (en) | Bicyclic peptide ligands specific for epha2 and uses thereof | |
| AU2024279075A1 (en) | Bicyclic peptide ligands specific for nectin-4 and uses thereof | |
| WO2024248859A1 (en) | Bicyclic peptide ligands specific for nectin-4 and uses thereof | |
| WO2024155790A2 (en) | Novel approach for treatment of cancer using immunomodulation | |
| WO2023136837A1 (en) | Use of tivozanib and durvalumab for treating hepatocellular carcinoma (hcc) | |
| EA047123B1 (ru) | Бициклические пептидные лиганды, специфические для нектина-4, и их применение | |
| AU2023449926A1 (en) | Bicyclic peptide ligands specific for epha2 and uses thereof | |
| WO2025056907A1 (en) | Bicyclic peptide ligands specific for nectin-4 and uses thereof | |
| WO2025125648A1 (en) | Bicyclic peptide complex for use in treating cancer | |
| WO2025125809A1 (en) | Bicyclic peptide ligands specific for nectin-4 and uses thereof | |
| WO2024258916A1 (en) | Stat3 degraders and uses thereof | |
| EA046145B1 (ru) | Фармацевтические композиции, содержащие конъюгат, содержащий токсин и бициклический пептид, и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |